TY - JOUR
T1 - Novel p53/p130 Axis in Bladder Tumors
AU - Mudryj, Maria
AU - Reay, Elizabeth
AU - Beckett, Laurel A
AU - Dandekar, Satya
AU - deVere White, Ralph W
AU - Gandour-Edwards, Regina F
PY - 2007/9
Y1 - 2007/9
N2 - Objectives: To identify the relationships between key components of the proliferative and apoptotic pathways in bladder tumors. Methods: A tissue array of 88 bladder tumors was assembled. Immunohistochemical analyses were used to investigate the relationship between nine different parameters: stage, proliferation (Ki67), apoptosis (in situ DNA nick end labeling), the anti-apoptotic protein Bcl-2, tumor suppressors p53 and retinoblastoma protein (Rb), the Rb-related protein p130, cyclin E, and the cyclin-dependent kinase inhibitor p27. The protein expression in each tumor was reported as the percentage of positively staining cells. Results: The analysis focused on Stage 1 to 3 tumors. Analysis found that p53 expression increased progressively with stage, and Rb and p27 decreased with increasing stage. Overall, the cyclin E levels correlated with the proliferative index. Cyclin E levels were low in Stage 1 tumors and elevated in Stage 2 tumors, but were decreased in Stage 3 tumors. Multivariate analysis uncovered a correlation between cyclin E and proliferation (Ki67) and a weak correlation between p53 and Bcl-2 and between p27 and Rb. A strong correlation was found between the expression of p53 and p130, which was apparent in Stages 1 and 3, but not in Stage 2. Furthermore, high levels of p130 protein were detected primarily in the cytoplasm. Conclusions: These results suggest a novel p53/p130 axis in bladder tumors.
AB - Objectives: To identify the relationships between key components of the proliferative and apoptotic pathways in bladder tumors. Methods: A tissue array of 88 bladder tumors was assembled. Immunohistochemical analyses were used to investigate the relationship between nine different parameters: stage, proliferation (Ki67), apoptosis (in situ DNA nick end labeling), the anti-apoptotic protein Bcl-2, tumor suppressors p53 and retinoblastoma protein (Rb), the Rb-related protein p130, cyclin E, and the cyclin-dependent kinase inhibitor p27. The protein expression in each tumor was reported as the percentage of positively staining cells. Results: The analysis focused on Stage 1 to 3 tumors. Analysis found that p53 expression increased progressively with stage, and Rb and p27 decreased with increasing stage. Overall, the cyclin E levels correlated with the proliferative index. Cyclin E levels were low in Stage 1 tumors and elevated in Stage 2 tumors, but were decreased in Stage 3 tumors. Multivariate analysis uncovered a correlation between cyclin E and proliferation (Ki67) and a weak correlation between p53 and Bcl-2 and between p27 and Rb. A strong correlation was found between the expression of p53 and p130, which was apparent in Stages 1 and 3, but not in Stage 2. Furthermore, high levels of p130 protein were detected primarily in the cytoplasm. Conclusions: These results suggest a novel p53/p130 axis in bladder tumors.
UR - http://www.scopus.com/inward/record.url?scp=34648832129&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34648832129&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2007.05.002
DO - 10.1016/j.urology.2007.05.002
M3 - Article
C2 - 17905135
AN - SCOPUS:34648832129
VL - 70
SP - 608
EP - 612
JO - Urology
JF - Urology
SN - 1527-9995
IS - 3
ER -